Regaliz Medicare Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.20 Cr
as on 16-11-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 43.07%
(FY 2023)
- Profit -1.82%
(FY 2023)
- Ebitda 11.60%
(FY 2023)
- Net Worth 41.08%
(FY 2023)
- Total Assets 23.84%
(FY 2023)
About Regaliz Medicare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 5.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Piyush Shah, Dipak Desai, Pallav Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PLC285743
- Company No.
285743
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
09 Sep 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Regaliz Medicare?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyush Shah  | Director | 06-Mar-2019 | Current |
| Dipak Desai | Director | 09-Sep-2016 | Current |
| Pallav Shah | Director | 09-Sep-2016 | Current |
| Himanshu Desai | Director | 09-Sep-2016 | Current |
Financial Performance of Regaliz Medicare.
Regaliz Medicare Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 43.07% increase. The company also saw a slight decrease in profitability, with a 1.82% decrease in profit. The company's net worth Soared by an impressive increase of 41.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regaliz Medicare?
In 2023, Regaliz Medicare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aurochem Laboratories (India) Private LimitedActive 27 years 27 daysPiyush Shah, Dipak Desai and 1 more are mutual person
Aurochem Pharmaceuticals (India) Private LimitedActive 30 years 1 monthPiyush Shah, Pallav Shah and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Regaliz Medicare?
Regaliz Medicare has a workforce of 371 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regaliz Medicare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regaliz Medicare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
